US Patent Issued to Ventus Therapeutics U.S. on May 27 for "Pyrido-[3,4-dpyridazine amine derivatives useful as NLRP3 inhibitors" (Canadian Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,351, issued on May 27, was assigned to Ventus Therapeutics U.S. Inc. (Waltham, Mass.).

"Pyrido-[3,4-dpyridazine amine derivatives useful as NLRP3 inhibitors" was invented by Stephane Dorich (Pointe-Claire, Canada) and Stephane Ciblat (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of NLRP3 of Formula (I):or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as define...